Inci I, Ozçelik C, Ulkü R, Tuna A, Eren N
Department of Thoracic and Cardiovascular Surgery, Dicle University School of Medicine, Diyarbakir, Turkey.
Chest. 1998 Jul;114(1):160-5. doi: 10.1378/chest.114.1.160.
To evaluate the role of intrapleural fibrinolytic treatment (IPFT) in traumatic clotted hemothorax.
Between August 1995 and February 1997, 24 patients with traumatic clotted hemothorax were included. Streptokinase (SK), 250,000 IU, or urokinase (UK), 100,000 IU, diluted in 100 mL of saline solution was given daily. We administered 5.0+/-1.8 (range, 2 to 9) doses of SK or 6.25+/-5.97 (range, 2 to 15) doses of UK.
Dicle University School of Medicine, Thoracic and Cardiovascular Surgery Department.
Complete response, which was defined as resolution of symptoms with complete drainage of fluid and no residual space radiographically, occurred in 15 (62.5%) patients. Partial response, which was defined as resolution of symptoms with a small pleural cavity, occurred in seven (29.2%) patients. Two patients (8.3%) required decortication; they were defined as nonresponders. The mean period of time between the diagnosis and fibrinolytic treatment (FT) was 11.65+/-6.38 (range, 4 to 25) days. There were no complications related to IPFT. There was no mortality during the course of IPFT.
The use of intrapleural fibrinolytic agents has resulted in resolution of clotted hemothorax with an overall success rate of 91.7%. We recommend that IPFT should be added to the algorithm for management of clotted hemothorax before proceeding with minithoracotomy or pleural decortication.
评估胸腔内纤维蛋白溶解治疗(IPFT)在外伤性凝固性血胸治疗中的作用。
1995年8月至1997年2月期间,纳入24例外伤性凝固性血胸患者。每天给予250,000国际单位链激酶(SK)或100,000国际单位尿激酶(UK),用100毫升盐溶液稀释。我们给予了5.0±1.8(范围2至9)剂量的SK或6.25±5.97(范围2至15)剂量的UK。
狄克莱大学医学院胸心血管外科。
完全缓解定义为症状消失,液体完全引流,影像学上无残留腔隙,15例(62.5%)患者出现完全缓解。部分缓解定义为症状消失,胸腔较小,7例(29.2%)患者出现部分缓解。2例(8.3%)患者需要行胸膜剥脱术;他们被定义为无反应者。诊断与纤维蛋白溶解治疗(FT)之间的平均时间为11.65±6.38(范围4至25)天。没有与IPFT相关的并发症。IPFT过程中无死亡病例。
胸腔内使用纤维蛋白溶解剂可使凝固性血胸得到缓解,总体成功率为91.7%。我们建议在进行小开胸手术或胸膜剥脱术之前,应将IPFT纳入凝固性血胸的治疗方案中。